Core Viewpoint - The company reported a revenue of 1.593 billion yuan for the first three quarters, reflecting a year-on-year increase of 7.71%, but also recorded a net loss attributable to shareholders of 24.0489 million yuan, with a basic loss per share of 0.0173 yuan [1] Financial Performance - Revenue for the first three quarters reached 1.593 billion yuan, which is a 7.71% increase compared to the previous year [1] - The net loss attributable to shareholders was 24.0489 million yuan [1] - Basic loss per share was reported at 0.0173 yuan [1]

Core Insights - The company reported a revenue of 1.593 billion yuan for the first three quarters, representing a year-on-year increase of 7.71% [1] - The net loss attributable to shareholders was 24.0489 million yuan, with a basic loss per share of 0.0173 yuan [1] Financial Performance - Revenue: 1.593 billion yuan, up 7.71% year-on-year [1] - Net Loss: 24.0489 million yuan [1] - Basic Loss per Share: 0.0173 yuan [1]

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就 因 本 公 告 全 部 或 任 何 部 份 內 容 而 產 生 或 因 倚 賴 該 等 內 容 而 引 致 的 任 何 損 失 承 擔 任 何 責 任。 CSPC PHARMACEUTICAL GROUP LIMITED 石藥集團有限公司 （股份代號：1093） （於香港註冊成立之有限公司） 石 藥 創 新 製 藥 股 份 有 限 公 司 截 至2025年9月30日 止 九 個 月 之 未 經 審 核 財 務 資 料 按 深 圳 證 券 交 易 所 之 相 關 規 定，石 藥 集 團 有 限 公 司（「本 公 司」）附 屬 公 司 石 藥 創 新 製 藥 股 份 有 限 公 司（「石 藥 創 新」，其 股 份 於 深 圳 證 券 交 易 所 創 業 板 上 市（股 票 代 碼：300765））， 已 於2025年10月27日 發 佈 其 截 至2025年9月30日 止 九 ...

Core Viewpoint - Newell reported a revenue of 543 million yuan for Q3 2025, marking a year-on-year increase of 7.18%, but faced a net loss attributable to shareholders of 21.3 million yuan, a significant decline of 1025.45% compared to the previous year [1] Financial Performance - For the first three quarters of 2025, the company achieved a total revenue of 1.593 billion yuan, reflecting a year-on-year growth of 7.71% [1] - The net loss attributable to shareholders for the first three quarters was 24.0489 million yuan, which represents a year-on-year decline of 117.26% [1]

Core Viewpoint - XinNuoWei (300765.SZ) reported a revenue of 1.593 billion yuan for the first three quarters of 2025, reflecting a year-on-year growth of 7.71% [2] Financial Performance - The net loss attributable to shareholders of the listed company was 24.0489 million yuan [2] - The net loss attributable to shareholders, excluding non-recurring gains and losses, was 64.8209 million yuan [2] - The basic loss per share was 0.0173 yuan [2]

转自：证券时报 人民财讯10月27日电，新诺威(300765)10月27日发布2025年第三季度报告，前三季度实现营业收入15.93 亿元，同比增长7.71%；归母净利润亏损2404.89万元。第三季度营业收入5.43亿元，同比增长7.18%； 归母净利润亏损2130.27万元。 ...

证券代码：300765 证券简称：新诺威 公告编号：2025-083 石药创新制药股份有限公司 二、董事会会议审议情况 经与会董事充分讨论，本次会议审议并通过了如下议案： （一）审议并通过《关于公司<2025 年第三季度报告>的议案》 经审议，董事会认为：《2025 年第三季度报告》的内容符合法律、行政法规、 中国证券监督管理委员会和深圳证券交易所的相关规定，报告内容真实、准确、 完整，不存在任何虚假记载、误导性陈述或者重大遗漏。 具体内容详见公司刊载于中国证监会指定创业板信息披露网站巨潮资讯网 （www.cninfo.com.cn）上的相关公告。 第六届董事会第二十七次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 石药创新制药股份有限公司（以下简称"公司"或"上市公司"）第六届董 事会第二十七次会议（以下简称"本次会议"）于 2025 年 10 月 27 日在公司会议 室以现场加通讯表决相结合的方式召开，会议通知于 2025 年 10 月 22 日以专人 送出、电话通知等方式送达全体董事。 会议由公司董事长姚兵先生主持 ...

Financial Performance - The company's revenue for Q3 2025 was ¥543,456,419.92, representing a year-over-year increase of 7.18%[5] - The net profit attributable to shareholders was -¥21,302,733.89, a significant decline of 1,025.45% compared to the same period last year[5] - Total operating revenue for Q3 2025 reached CNY 1,593,014,097.66, an increase of 7.7% compared to CNY 1,478,923,011.81 in the same period last year[19] - Net profit for the period was a loss of CNY 310,248,602.63, compared to a loss of CNY 46,481,389.50 in the same quarter last year[19] - Basic and diluted earnings per share were both reported at -0.0173, compared to 0.0995 in the same quarter last year[19] Cash Flow - The net cash flow from operating activities for the year-to-date was -¥175,121,559.93, showing an improvement of 81.67% from the previous year[11] - Operating cash flow for the current period was -175,121,559.93 CNY, an improvement from -955,575,497.94 CNY in the previous period[22] - Cash inflow from operating activities totaled 1,531,540,956.53 CNY, compared to 1,474,347,715.04 CNY in the prior year[22] - The company reported a net cash flow from investment activities of -244,872,397.40 CNY, an improvement from -918,868,799.42 CNY in the previous period[22] - The company’s cash outflow for financing activities was 54,933,251.68 CNY, down from 691,589,728.40 CNY in the previous period[23] Assets and Liabilities - The total assets at the end of the reporting period were ¥6,210,880,638.20, reflecting a 3.13% increase from the end of the previous year[5] - Total liabilities increased to CNY 2,046,053,463.52, compared to CNY 1,526,185,458.97 in the previous year[18] - The equity attributable to shareholders of the parent company decreased to CNY 3,687,757,832.28 from CNY 3,730,544,275.59 year-on-year[18] - The company reported a significant increase in accounts payable, which rose to CNY 474,991,650.54 from CNY 303,326,595.53 year-on-year[18] Research and Development - Research and development expenses increased by 49.56% year-over-year, totaling ¥683,435,255.69, driven by enhanced investment in innovation[10] - Research and development expenses rose significantly to CNY 683,435,255.69, a 49.5% increase from CNY 456,957,233.20 in the previous year[19] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 16,410, with the largest shareholder holding 73.83% of the shares[12] - The company plans to increase its stake in Giant Bio by acquiring 29% of its shares for a cash consideration of RMB 1.1 billion, raising its ownership from 51% to 80%[14] - The acquisition of shares is expected to create greater value for all shareholders[14] Government Support - The company received government subsidies totaling ¥4,249,218.58 during the quarter, contributing to a year-to-date total of ¥71,944,745.16[6] Strategic Focus - The company is focused on enhancing its strategic layout in the innovative biopharmaceutical sector[14] - The company's financial position reflects a strong emphasis on managing liquidity and receivables effectively[16] - The ongoing acquisition process is being conducted in an orderly manner, with further details available on the company's official announcements[14]

Group 1 - The core point of the news is that XinNuoWei's stock price has been declining, with a drop of 5.01% on October 23, reaching 38.89 CNY per share, and a total market capitalization of 54.625 billion CNY [1] - XinNuoWei has experienced a cumulative decline of 6.74% over the past three days [1] - The company, founded on April 5, 2006, specializes in the research, production, and sales of functional foods, with 88.93% of its revenue coming from functional foods and raw materials [1] Group 2 - Citic Securities Fund has a significant holding in XinNuoWei, with its fund "Citic Jiankang A" holding 225,000 shares, accounting for 3.86% of the fund's net value [2] - The fund has incurred a floating loss of approximately 461,200 CNY today and a total floating loss of 666,000 CNY during the three-day decline [2] - The fund manager, Xie Wei, has been in position for 7 years and 143 days, with the fund's total asset size at 1.987 billion CNY [2]

Company Overview - XinNuoWei is primarily engaged in the research, production, and sales of functional foods, with 88.93% of its revenue coming from this segment, followed by biopharmaceuticals at 8.91% and other sources at 2.16% [1] - The company was established on April 5, 2006, and went public on March 22, 2019 [1] Stock Performance - As of October 23, XinNuoWei's stock price decreased by 2.03%, trading at 40.11 CNY per share, with a market capitalization of 56.338 billion CNY [1] - Year-to-date, the stock has increased by 50.96%, but has seen declines of 8.28% over the last five trading days, 17.09% over the last 20 days, and 23.01% over the last 60 days [1] Financial Performance - For the first half of 2025, XinNuoWei reported revenue of 1.05 billion CNY, a year-on-year increase of 7.99%, while the net profit attributable to shareholders was a loss of 2.7461 million CNY, a decrease of 102% compared to the previous year [2] Shareholder Information - As of October 20, XinNuoWei had 16,400 shareholders, a decrease of 2.77% from the previous period, with an average of 75,892 circulating shares per shareholder, an increase of 2.85% [2] - The company has distributed a total of 651 million CNY in dividends since its A-share listing, with 500 million CNY distributed over the last three years [3] Institutional Holdings - As of June 30, 2025, the second-largest circulating shareholder is Hong Kong Central Clearing Limited, holding 20.9991 million shares, an increase of 5.045 million shares from the previous period [3] - New institutional shareholders include Zhongou Medical Innovation Stock A and Huatai-PineBridge Innovation Medical Mixed A, while others like E Fund Healthcare Industry Mixed A have exited the top ten circulating shareholders list [3]